Menicon Company (7780) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
13 May, 2026Executive summary
Net sales increased 3.4% year-over-year to ¥125,605 million, driven by growth in daily disposable contact lenses and MELS Plan membership, with strong performance in Japan, Europe, and North America.
EBITDA rose 14.1% year-over-year, reflecting higher gross profit and continued investment for growth.
Operating profit increased 2.2% to ¥10,236 million, while ordinary profit surged 15.2% to ¥11,021 million, aided by foreign exchange gains.
Profit attributable to owners of parent grew 5.7% to ¥5,916 million, despite extraordinary losses from impairment in the orthokeratology segment, especially in China.
Comprehensive income jumped to ¥13,194 million, reflecting significant foreign currency translation gains.
Financial highlights
FY2025 net sales: JPY 125.6 bn (+3.4% YoY); gross profit: JPY 67.6 bn (+3.9% YoY); operating profit: JPY 10.2 bn (+2.2% YoY); EBITDA: JPY 21.0 bn (+14.1% YoY); profit attributable to owners: JPY 5.9 bn (+5.7% YoY).
Cost of sales ratio improved to 46.2% (-0.3pt YoY); operating profit margin at 8.1%.
SGA expenses increased 4.3% YoY, reflecting investments in new plants and personnel.
Cash and cash equivalents at year-end decreased by ¥9,454 million to ¥32,410 million, mainly due to capital expenditures and treasury share acquisition.
Dividend per share was ¥28, with a payout ratio of 35.4%.
Outlook and guidance
FY2026 net sales forecast: JPY 133.0 bn (+5.9% YoY); operating profit: JPY 11.0 bn (+7.5% YoY); EBITDA: JPY 22.6 bn (+7.3% YoY); profit attributable to owners: JPY 6.5 bn (+9.9% YoY).
Ordinary profit is expected to decrease by 4.7% YoY due to anticipated cost increases.
Dividend forecast for FY2026 is JPY 28 per share, maintaining a payout ratio around 30%.
Market growth is expected in the contact lens sector, but risks include rising costs, FX volatility, and inflation.
Latest events from Menicon Company
- Strong 1-DAY lens demand and MELS Plan subscriptions drive global growth and market expansion.7780
Investor presentation13 May 2026 - Profit and sales rose, driven by daily disposable lens growth and global expansion.7780
Q3 202613 Feb 2026 - 1-DAY lens sales and price hikes lifted sales, but profits fell on higher costs and FX losses.7780
Q2 202614 Nov 2025 - Profits fell sharply despite stable sales, as investments and FX losses weighed on margins.7780
Q1 20268 Aug 2025 - Sales and profits rose on strong lens demand, with margin pressure expected ahead.7780
Q2 202513 Jun 2025 - Sales and profit rose on Vision Care strength, with robust full-year outlook maintained.7780
Q1 202513 Jun 2025 - Profit and sales surged on daily lens demand; growth to continue with new capacity and expansion.7780
Q4 20256 Jun 2025 - Profits rose on lens demand and price hikes, but China remains a challenge.7780
Q3 20255 Jun 2025